| 证券代码:300151 | 证券简称：昌红科技 | 公告编号：2023-093 | | --- | --- | --- | | 债券代码:123109 | 债券简称：昌红转债 | | 深圳市昌红科技股份有限公司 关于全资子公司对外投资的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、对外投资概述 1、对外投资的基本情况 深圳市昌红科技股份有限公司（以下简称"公司"）全资子公司德盛投资有限 公司（以下简称"德盛投资"）拟认购 PharmaSens AG（以下简称"PharmaSens"） 新发行记名股份 33,569 股，发行价格 100 瑞士法郎/股，预计占其本次发行后总 股本比例的 5%股权，交易金额 3,356,900 瑞士法郎（具体金额以实际汇出当天汇 率计算为准）。本次投资认购资金来源于德盛投资自有资金。 2、董事会审议情况 根据《深圳证券交易所创业板股票上市规则》《公司章程》等相关规定，本 次交易在公司总经理审批权限范围内，无需提交公司董事会及股东大会审议。 3、本次交易事项不构成关联交易，亦不构成《上市公司重大资产重组管理 办法》规定 ...

| 证券代码:300151 | 证券简称：昌红科技 | 公告编号：2023-092 | | --- | --- | --- | | 债券代码:123109 | 债券简称：昌红转债 | | 深圳市昌红科技股份有限公司 关于 2022 年员工持股计划第一批股票出售完毕的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 深圳市昌红科技股份有限公司（以下简称"公司"）于 2022 年 3 月 9 日召开 第五届董事会第十五次会议及第五届监事会第十三次会议，并于 2022 年 3 月 30 日召开 2022 年第一次临时股东大会，审议通过《关于公司<2022 年员工持股计 划（草案）>及其摘要的议案》、《关于公司<2022 年员工持股计划管理办法>的议 案》、《关于提请股东大会授权董事会办理员工持股计划相关事宜的议案》等相关 议案；于 2022 年 6 月 24 日召开第五届董事会第十九次会议及第五届监事会第十 六次会议，并于 2022 年 7 月 11 日召开 2022 年第二次临时股东大会，审议通过 《关于修订 2022 年员工持股计划相关事项的议案》。具体内容 ...

| 证券代码:300151 | 证券简称：昌红科技 | 公告编号：2023-091 | | --- | --- | --- | | 债券代码:123109 | 债券简称：昌红转债 | | 深圳市昌红科技股份有限公司 关于 2022 年员工持股计划第一个锁定期届满 暨业绩考核达成的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 深圳市昌红科技股份有限公司（以下简称"公司"）于 2022 年 3 月 9 日召开 第五届董事会第十五次会议及第五届监事会第十三次会议，并于 2022 年 3 月 30 日召开 2022 年第一次临时股东大会，审议通过《关于公司<2022 年员工持股计 划（草案）>及其摘要的议案》、《关于公司<2022 年员工持股计划管理办法>的议 案》、《关于提请股东大会授权董事会办理员工持股计划相关事宜的议案》等相关 议案；于 2022 年 6 月 24 日召开第五届董事会第十九次会议及第五届监事会第十 六次会议，并于 2022 年 7 月 11 日召开 2022 年第二次临时股东大会，审议通过 《关于修订 2022 年员工持股计划相关事 ...

法律意见书 中国 深圳 福田区 益田路6001号 太平金融大厦11、12楼 邮政编码：518038 11/F、12/F., TAIPING FINANCE TOWER, NO.6001 YITIAN ROAD, SHENZHEN, P.R. CHINA 电话（Tel.）：（86-755) 88265288 传真（Fax.）：（86-755）88265537 网站（Website）：www.sundiallawfirm.com 广东信达律师事务所 关于深圳市昌红科技股份有限公司 2023年第二次临时股东大会的 法律意见书 信达会字（2023）第312号 致：深圳市昌红科技股份有限公司 广东信达律师事务所（以下称"信达"）接受深圳市昌红科技股份有限公司 （以下称"公司"）的委托，指派信达律师出席公司2023年第二次临时股东大会（以 下称"本次股东大会"），对本次股东大会的合法性进行见证。 信达律师根据《中华人民共和国公司法》（以下称"《公司法》"）、《上市 公司股东大会规则》（以下称"《股东大会规则》"）等法律、法规和规范性法律 文件以及《深圳市昌红科技股份有限公司章程》（以下称"《公司章程》"）的规 定，就公司 ...

深圳市昌红科技股份有限公司 2023 年第三季度报告 证券代码：300151 证券简称：昌红科技 公告编号：2023-083 债券简称: 昌红转债 债券代码: 123109 深圳市昌红科技股份有限公司 2023 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 1 深圳市昌红科技股份有限公司 2023 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |-----------------------------------------------------|------------------|--------- ...

Group 1: Market Environment and Challenges - The company faces instability in the market due to multiple factors, including post-pandemic effects, a weak medical testing industry, and reduced market demand, leading to challenges in domestic orders [2] - International trade conflicts have also impacted the company's PCB business, with overall domestic market demand experiencing a decline [2] - Despite challenges, overseas factory orders remain stable, prompting the company to invest and expand its overseas production bases [2] Group 2: Business Performance and Future Outlook - The medical business has seen significant development opportunities during the pandemic, gaining recognition from numerous international clients and entering their supply chains [2] - The company plans to collaborate comprehensively with domestic and international clients in areas such as immunology, chemiluminescence, and molecular diagnostics in the second half of the year [3] - The market for medical consumables is substantial, with a single international IVD giant's annual global procurement reaching 8 billion RMB, and the blood glucose monitoring market potentially reaching several billion USD [4] Group 3: Product Development and Revenue Generation - The company is currently validating its wafer carrier products, which include FOUP and FOSB, but has not yet generated revenue from these products [4] - The company is focusing on differentiated product development strategies, starting with the most challenging 12-inch wafer carriers [4] - The mold projects reported are newly added concepts from the last 12 months, and the company will continue to disclose operational updates to keep investors informed [4]

Market Presence - The company primarily operates in developed markets such as Europe, the United States, and Japan, with a high proportion of foreign sales revenue[1] - The company has subsidiaries in various regions, including Hong Kong, Vietnam, and the Philippines, indicating a broad market presence[93] Financial Performance - The company reported a total revenue of 288,944,716.02 yuan for the reporting period, with a decrease of 604,874.57 yuan compared to the previous period[63] - The company's operating revenue for the first half of 2023 was ¥513,942,535.16, a decrease of 9.61% compared to ¥568,609,447.44 in the same period last year[114] - Net profit attributable to shareholders was ¥42,572,447.72, down 39.38% from ¥70,232,128.72 year-on-year, while the net profit after deducting non-recurring gains and losses was ¥33,847,103.77, a decrease of 43.82%[114] - The basic and diluted earnings per share were both ¥0.08, representing a decline of 42.86% compared to ¥0.14 in the previous year[114] - The company's total assets at the end of the reporting period were ¥2,089,105,420.94, down 6.52% from ¥2,234,719,706.75 at the end of the previous year[114] - The net assets attributable to shareholders decreased by 2.67% to ¥1,260,422,236.27 from ¥1,295,002,591.59 at the end of the previous year[114] - The company reported a net cash flow from operating activities of ¥94,875,766.23, an increase of 11.60% compared to ¥85,015,491.41 in the same period last year[114] Investment and Projects - The company has initiated a joint investment project with Hubei Dinglong Holdings to establish Zhejiang Dinglong Weibo Precision Technology Co., focusing on semiconductor wafer carrier manufacturing[25] - The semiconductor wafer carrier production facility is nearing completion, with production and testing equipment currently being debugged and samples sent to customers for validation[143] - The company has invested ¥5,681.22 million in the expansion of high-end medical equipment and consumables production lines, achieving an investment progress of 92.36%[183] - The high-end medical equipment and consumables production line expansion project has an investment commitment of RMB 32,500 million, with 92.36% of the investment completed[197] - The working capital supplement project has a total investment commitment of RMB 12,273.77 million, with 100% of the investment completed[197] Corporate Governance - The company has established a comprehensive corporate governance structure and internal control system to ensure fair treatment of all shareholders[14] - The annual shareholders' meeting held on May 16, 2023, had an investor participation ratio of 48.94%[76] - The board of directors and supervisory board have been re-elected during the annual shareholders' meeting[76] Environmental and Social Responsibility - The company is actively involved in environmental protection and sustainable development, adhering to relevant regulations for waste management[17] - The company emphasizes its commitment to environmental and social responsibilities in its report[95] - The company has no major environmental issues reported during the period[71] Research and Development - The company has established a relatively complete R&D system in precision mold design and manufacturing, focusing on protecting core technologies through patents and legal means[75] - The company has established a comprehensive R&D platform, including the Guangdong Precision Injection Molding Engineering Technology Research Center and the Shanghai Emerging Medical Devices and Life Sciences R&D Center[169] - The company focuses on precision mold design, manufacturing, and automation R&D, ensuring rapid response and diversified customization capabilities to meet customer needs[145] - The company has a strong R&D team with deep theoretical knowledge and rich industry experience, continuously advancing core technologies in high-precision medical molds and automation[146] - The company's R&D investment increased by 45.93% to ¥29,640,689.97, primarily due to higher salaries and stock-based compensation for R&D personnel[151] Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares for the half-year period[6] - The company plans not to distribute cash dividends, issue bonus shares, or increase capital using reserves for the fiscal year 2023[87] - As of the reporting period, the company has a total of 502,507,912 shares outstanding, with no significant changes in shareholding structure[35] - The company has a total of 184,487,713 shares with limited sale conditions, representing 36.71% of total shares, which decreased by 2,878,731 shares[51] - The company holds 318,020,199 unrestricted shares, accounting for 63.29% of total shares, with an increase of 2,878,846 shares[51] Risk Management - The company has disclosed potential risks and corresponding countermeasures in the management discussion and analysis section of the report[100] - The company faces risks related to industry policy changes that could impact the medical consumables sector, emphasizing the need for adaptive management strategies[187] Cash Flow and Assets - Cash and cash equivalents at the end of the reporting period amounted to ¥372,380,581.71, representing 17.82% of total assets, a decrease of 5.14% from the previous year[176] - Accounts receivable totaled ¥254,658,369.27, accounting for 12.19% of total assets, down by 1.02% year-on-year[176] - Inventory stood at ¥159,464,287.85, which is 7.63% of total assets, reflecting a decrease of 0.83% compared to the previous year[176] - Fixed assets increased to ¥419,898,183.50, making up 20.10% of total assets, an increase of 4.69% from last year[176] - The company reported a total of ¥29,897,793.45 in intangible assets, down from ¥30,210,859.35 at the end of the previous year[178] Compliance and Legal Matters - The company has no significant related party transactions during the reporting period[39] - There are no derivative investments reported for the company during the reporting period[55] - The company has no violations regarding external guarantees during the reporting period[73] - The company has no significant litigation or arbitration matters during the reporting period[80] - The financial report for the first half of 2023 is confirmed to be true, accurate, and complete by the company's management[99] - The company has established a dedicated account for the management of raised funds, ensuring strict compliance with the regulatory agreement[197] - No changes in the use of raised funds have been reported, maintaining a 0.00% change ratio[197] - The company has disclosed that the use of raised funds is in good condition, with no significant violations reported[197]

证券代码: 300151 证券简称：昌红科技 债券代码: 123109 债券简称: 昌红转债 深圳市昌红科技股份有限公司 投资者关系活动记录表 编号：2023-007 | --- | --- | --- | |----------------------------|----------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | □特定对象调研 □ | 分析师会议 | | 投资者关系活动类别 | □媒体采访 □□新闻发布会 □□现场参观 | 业绩 ...

证券代码: 300151 证券简称：昌红科技 债券代码: 123109 债券简称: 昌红转债 深圳市昌红科技股份有限公司 投资者关系活动记录表 编号：2023-006 | --- | --- | --- | |----------------------------|----------------------------------------------------------|--------------------------------------------------------------------------------------------| | | □特定对象调研 □ | 分析师会议 | | 投资者关系活动类别 | □媒体采访 □□新闻发布会 □□√现场参观 | 业绩说明会路演活动 | | | □其他 | | | | | 建投投资余蔡一；天安人寿李勇钢；太平资产李涛；国泰租赁郭 | | | | 梦颖、宁雪帆；兴银资本张黎明；瑞华控股陶光绪；东方嘉富周 | | | | 辉；永安期货姚沁源；锦绣中和冯奕健；睿郡资产苏华立；涌津 | | 参与单位名称 | | 投资傅逞强；北京泰德圣基金李妮 ...

证券代码: 300151 证券简称：昌红科技 债券代码: 123109 债券简称: 昌红转债 深圳市昌红科技股份有限公司 投资者关系活动记录表 编号：2023-005 | --- | --- | --- | |----------------------------|----------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | □特定对象调研 □ | 分析师会议 | | 投资者关系活动类别 | □媒体采访 □□新闻发布会 □□√现场参观 | 业绩说明会√路演活动 | | | □其他 | | | | ...